Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,401–13,500 of 15,747
Ulloa, E. R., He, K., Chung, E., Nieves, D. J., Michalik, D. E., & Afghani, B. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch12
Changes in COVID-19 Vaccine Hesitancy within Pennsylvania over the Course of the Pandemic
Harmon, J., Endy, M. C., Sulzinski, M. A., et al. (2023) · Guthrie Journal · doi:10.3138/guthrie-2023-0005
SARS-CoV-2 Antibody Status after the BNT162b2 Vaccine in Healthcare Workers
Onishi, S., YAMAZAKI, A., Kikuchi, K., Shimamura, Y., Sugaya, F., & Anbo, Y. (2022) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.37.10 · Cited by 2
Mostafa, H. H., & Pinsky, B. A. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0093
AliSher, A. N., Siraj, S., Greyson, D. L., Shaik, S., Ndaba, N., Myburgh, N., Top, K. A., the International Network of Special Immunization Services (INSIS) Investigators, Chen, R., Gutu, K., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2711466
“A semi-structured interview guide was developed and pilot tested with two individuals who were not included in the study to evaluate clarity and relevance prior to use (Supplemental Material 1).”
The role of COVID-19 vaccination
Lin, E. Y., Behrouzi, B., & Udell, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00015-7
Гагикович, В. А., Teplova, N. V., Евсиков, Е. М., Chobanyan, M. A., & Борисовна, Б. Л. (2026) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-gcp-0010
Multisystem Inflammatory Syndrome in an Adult After COVID-19 Vaccination
Chien, K., Duffett, L. D., & Scarvelis, D. (2022) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v17i2.593
Chowdhury, S. R., Chakrabarty, S., Chakraborti, M., & Das, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85730-7.00009-6
A Social Annotation Tool for Introductory Statistics
Tempesti, T. (2026) · Teaching Statistics · doi:10.1002/test.70051
Lanata, C. F., Ecker, L., Cornejo, R., Celis, C. R., Díaz-Parra, C. D. P., de León, S. A. R. P., Flores, O., Ochoa, M., Peña, B., & Gil, A. I. (2021) · Diagnóstico · doi:10.33734/diagnostico.v60i3.305
Okoli, G. N., Murphy, C., Mak, L., Cheng, S. M. S., Peiris, M. J. S., & Cowling, B. J. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127687
Yousefi, M., Madih, A. N., Dalfardi, B., Shafieipour, M., Sajadi, S. M. K., & Behzadi, A. (2023) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid-140132
(2023) · doi:10.1101/2023.03.27.23287639
“A trial conducted of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 used a group sequential Bayesian design for the phase 3 portion of the trial that led to licensure [12].”
MethodRecent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development
Turan, G., Boggio, M. J., Othman, A. S., Nnaemeka, V., Hill, A. V. S., & Salman, A. M. (2026) · Vaccines · doi:10.3390/vaccines14030277 · Cited by 2
“…in lipid nanoparticle (LNP) formulation and the successful deployment of mRNA vaccine technology against SARS-CoV-2 during the COVID-19 pandemic [108]. mRNA vaccines offer several advantages over conventional platforms, including precise antigen design via in silico methods and stimulate immune…”
Galitsyna, E. V., Kulikova, E. A., Paveliev, I. A., Kuznetsova, O. S., Senina, A. S., & Gusev, A. B. (2024) · Genes and Cells · doi:10.17816/gc601855 · Cited by 1
Ramírez‐Ortiz, D., Moise, T., Alemohammad, S. Y., Aymat, M., Gray, A., Jean-Gilles, M. M., Sheehan, D. M., Ladner, R. A., & Trepka, M. J. (2025) · BMC Public Health · doi:10.1186/s12889-025-25017-9
Injection site reactions after COVID-19 mRNA vaccination
Lian, B. S., Choo, K. J. L., Chong, C. J., et al. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021508
Sun, Y., Zhu, B., Li, X., Luo, Z., & Bian, W. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1560973 · Cited by 2
Shrilall, C., Arbuthnot, P. B., & Ely, A. (2025) · Microorganisms · doi:10.3390/microorganisms13030604
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan
Shoji, N., Ito, S., Nojiri, S., Urasaki, W., Nara, T., Okuzawa, A., & Tobita, M. (2024) · Global Health & Medicine · doi:10.35772/ghm.2024.01053
Acute Myopericarditis After the Third Vaccination of BNT162b2 in a Middle-Aged Man
Nakawatase, S., Hayashi, T., Nakamura, S., et al. (2022) · Cureus · doi:10.7759/cureus.28857
“Several clinical trials show that mRNA vaccines have high effectiveness in preventing infection and decreasing the severity of COVID-19 [1].”
BackgroundImmunogenicity of the BBIBP-CorV Vaccine; An Observational Study from Pakistan
Jahanzeb, Z., Zahid, A., Hafeez-ud-din, Aslam, H., Kausar, S., & Israr, M. (2023) · Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · doi:10.48036/apims.v18i4.670
The Frankensteinification of Translational Gerontology
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0004
Briggs, F. B. S., Schmidt, H. K., Mateen, F. J., Buxhoeveden, S., Bebo, B. F., Fiol, J., Racke, M. K., Currie, K. M., Siefers, H., Crouthamel, S., et al. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.106253 · Cited by 1
The Safety of COVID-19 Vaccine Accepted in Patients with Rheumatic Immune Diseases
朱, 芳. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134763
Takatori, M., Nemoto, A., Hirotsu, Y., Mikawa, T., Honda, R., Ono, M., Endo, A., Shibamori, K., Shiozawa, R., Maejima, M., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01288-25
“The effectiveness of mRNA vaccines in reducing SARS-CoV-2 infection rates has been well-known in the general population and HCWs (8–12).”
Kopfschmerz zurückzuführen auf eine Substanz oder deren Entzug
Göbel, H. (2025) · Springer eBooks · doi:10.1007/978-3-662-68873-1_16
Effects of some biological factors on Coronavirus
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.05.058
Turabián, J. L. (2022) · MedPress Public Health and Epidemiolog · doi:10.33582/mpphe.2022.202209003 · Cited by 1
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Nakagami, H., & Yamasaki, S. (2024) · eLife · doi:10.7554/elife.89999.2
Lipid-based mRNA delivery systems
Das, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00012-4 · Cited by 1
Exploring Coronavirus Disease 2019 Risk Factors: A Text Network Analysis Approach
Kang, M.-A., & Lee, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062084 · Cited by 15
Favresse, J., Tré‐Hardy, M., Gillot, C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4760653
Self-inhibiting percolation and viral spreading in epithelial tissuePreprint
Xu, X., Nielsen, B. F., & Sneppen, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571279
Yıldırım, T. D., Akleylek, C., Yıldırım, D., Cinakli, H., Hakbilen, S., Coşkun, B. N., Okyar, B., Işık, Ö. Ö., Sağır, R. P., Apaydın, H., et al. (2025) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/apjtm.apjtm_253_24 · Cited by 1
Vacunas asignadas y aplicadas por dosis contra COVID-19 en Colombia: un avance significativo
Pinzón, J. E. D. (2023) · Cultura científica · doi:10.38017/1657463x.822
Riedmann, U., Sprenger, M., Ioannidis, J. P. A., et al. (2025) · medRxiv · doi:10.1101/2025.08.20.25334029
Vijayalakshmi, S., Manivannane, K., & Malarvizhi, N. (2021) · Shanlax International Journal of Arts Science and Humanities · doi:10.34293/sijash.v9i2.4384
Sønstevold, T. (2021) · NVA (Nasjonalt vitenarkiv) · Cited by 2
Granatir, S., Acosta, F. M., Pantoja, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.11.612487
“Despite effective vaccines 8 and therapeutics 9,10 , SARS-CoV-2 continues to circulate and can lead to complications, particularly in high-risk groups.”
BackgroundClarke, C., Esposito, D. B., Urdaneta, V., Mukherjee, P., & Buttery, A. K. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2662118
“9 Although the clinical profile of mRNA COVID-19 vaccines was well defined in large clinical trials, 10,11 it was of primary importance to demonstrate their favorable benefit–risk profiles when used at a large population level.”
Itamochi, M., Yazawa, S., Saga, Y., Shimada, T., Fukuyama, K., Oishi, K., & Tani, H. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102637 · Cited by 1
Sironi, M., & Gónzález‐Candelas, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28818-0.00012-4
Raheed, T., Therachiyil, L., Inchakalody, V. P., Peerapen, P., Younis, S. M., Ahmad, F., Jochebeth, A., Al-Suwaidi, A. K., Zaqout, A., Akbar, S., et al. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00962 · Cited by 1
Lock the Doors: The Myocarditis Disaster and a call for the broad examination of the CDC and FDA
Jablonowski, K. D., & Hooker, B. S. (2023) · Medical Research Archives · doi:10.18103/mra.v11i5.3907
Multiplexed spatial screening of lipid-based nanoparticles for extrahepatic messenger RNA targeting
Enzlein, T., Schumacher, J., Geisel, A., Keller, F., Houben, A., Walzer, K. C., Rittel, M. F., Fröhlich, B., Cairns, J. L., Cordes, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114728 · Cited by 2
Улюкин, И. М., Рассохин, В. В., Сечин, А. А., & Орлова, Е. С. (2024) · HIV Infection and Immunosuppressive Disorders · doi:10.22328/2077-9828-2024-16-3-25-35
The rise of biologics: the need for their inclusion in pharmacology curriculum of dentistry
Kaluarachchi, K., Osathanon, T. N., & Samaranayake, L. P. (2026) · BDJ · doi:10.1038/s41415-026-9540-y
Waghmare, A., Dadhe, R., Kobbe, R., Danziger‐Isakov, L. A., Sprinz, E., Muñoz, F. M., Gayed, J., Solan, R., Diya, O., Abraham, B., et al. (2026) · Vaccines · doi:10.3390/vaccines14070602
Self-citationWaki, K., Tani, H., Kawahara, E., Saga, Y., Shimada, T., Yamazaki, E., Koike, S., Morinaga, Y., Isobe, M., & Kurosawa, N. (2025) · eLife · doi:10.1101/2023.04.10.536311
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2024) · doi:10.7554/elife.89423.2
Kimoto, T., Sakai, S., Kameda, K., et al. (2022) · doi:10.22541/au.166798625.58661972/v1
Development of novel vaccines using nanomaterials against COVID-19
Chennamchetty, V. K., Kandi, S. C., & Rao, M. V. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99596-2.00012-1
Wang, J., Ai, J., Xiang, H., Zhang, Y., Hou, Z., Zhang, Q., Lv, J., Chen, S., Liu, C., Li, Q., et al. (2023) · Portal hypertension & cirrhosis · doi:10.1002/poh2.57
Psoriasiform Dermatitis Associated With the Moderna COVID-19 Messenger RNA Vaccine
Daneshbod (2022) · Cutis · doi:10.12788/cutis.0656
Kokogho, A., Crowell, T. A., Bain, P. A., Popal, S., Aleissa, M. M., Chang, J. B. P., Aleissa, D., Osamade, A., Novack, L. A., Heithoff, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3283799/v1
Bajči, M., Drljača, M., Turkulov, V., Pete, M., & Lendak, D. F. (2023) · Medicinski pregled · doi:10.2298/mpns2312344b
Katoto, P. D., Kakubu, M. A., Tamuzi, J. L., Brand, A., Ayuk, A. C., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · medRxiv · doi:10.1101/2023.01.20.23284812
RNASTOP: A Deep Learning Framework for mRNA Chemical Stability Prediction and Optimization
Lin, S., Chen, J., Sun, H., Zhang, Y., Yang, W., Tan, H., Wei, D., Jiang, Q., & Xiong, Y. (2026) · Genomics Proteomics & Bioinformatics · doi:10.64898/2026.03.18.712573 · Cited by 1
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.002.0004
Kisiel, J., Chojnicki, M., Kowala-Piaskowska, A. E., Wieczorowska–Tobis, K., Tobis, S., Religioni, U., Merks, P., & Neumann‐Podczaska, A. (2025) · Life · doi:10.3390/life15060879
He, Y., Wang, L., Williams, A. P., Valerio, T. I., Sun, Y., Bowman, J., Ricketts, S. D., Hammond, S., Sison, A., Alexandre, J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c11865
Erice, A., Nuño, N., Prieto, L., & Caballero, C. (2025) · Vaccines · doi:10.3390/vaccines13030310
“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines are effective at protecting against severe disease, hospitalization, and death caused by SARS-CoV-2 infection [1,2].”
Merker, V. L., Ahlawat, S., Avery, R. A., Bradford, D., Gross, A. M., Janusz, J. A., Lessing, A. J., Manth, L., McManus, M. L., Oberlander, B., et al. (2026) · Cancers · doi:10.3390/cancers18152463 · Cited by 1
“Clinical trials with decentralized components have led to regulatory approvals from the Food and Drug Administration (FDA) [16–18], bolstering the case for their expanded adoption.”
de Lima, V. A., Ferreira, R. D. S., Oliva, M. L. V., Andreata‐Santos, R., Janini, L. M., Maricato, J. T., Akamatsu, M. A., Ho, P. L., & Schenkman, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.15.528632
Understanding T-cell immunity elicited by SARS-CoV-2 mRNA vaccines
Jung, M. K., & Shin, E. (2025) · KOBRA Reports · doi:10.64066/kobrareports.25.0023
Young, J., He, E. M., Boone, D., Luehr, J., Tasnim, K., Turner, M., Ambatipudi, M., Gonzalez, P. C., Mooney, D. J., & Koh, E. G. L. (2021) · doi:10.14293/s2199-1006.1.sor-.ppaahgk.v1
“Vaccines that allow for safe and effective immunization are another valuable mitigation method [11-13].”
MethodCaractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
Dufloo, J. (2021) · theses.fr (ABES) · doi:10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8
Sasaki, E., Asanuma, H., Takahashi, Y., & Hasegawa, H. (2026) · International Immunology · doi:10.1093/intimm/dxag023
Aslan, T. K., Cantekin, I., Burucu, R., & Akdoğan, Y. (2024) · Ageing International · doi:10.1007/s12126-023-09536-7
“(Polack et al., 2020) These negative effects, however, are more common among young people, according to reports (A. Riad et al., 2021a, 2021b).”
Recent advancements in cancer vaccine developments: novel approaches
Ejeta, B. M., Das, M. K., Das, S., Bakare, F. F., Ayana, O. T., & Jamatia, T. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2026.2621220 · Cited by 2
Mohsenzadeh, A., Pourasgar, S., Borji, S., Bavari, S., Moghadam, E. E., Tanha, H. R., Mohsenzadeh, H., Kamali, K., Moghadam, Z. B., & Sabati, H. (2022) · Journal of Current Biomedical Reports · doi:10.61186/jcbior.3.3.172
Fujiyama, R., Fujiyama, K., Tada, H., Sumi, T., & Moriuchi, H. (2024) · Journal of Oral Science · doi:10.2334/josnusd.24-0080
SARS-CoV-2: A Comprehensive Insight into DNA, RNA, Subunit, and Viral Vaccines
Tabassum, S. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_18
cSMRTS for cancer therapeutics
Ravid, S., Hazan‐Halevy, I., & Peer, D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.054
Gender and personalized medicine: Methodological and ethical pitfalls
Legato, M. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0011
Ahmed, K. H. O., Munsoor, M. M., Ahmed, A., et al. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/iqabjqe3bs
Jankowski, J. M., Sik, K., & Job, V. (2025) · PLoS ONE · doi:10.1371/journal.pone.0338367
“We described that the Scimed vaccine was introduced shortly after the SciX virus was discovered and had a similar efficacy level as the Pfizer-Biontech vaccine [34].”
Statistical innovation: Transforming pharmaceutical research and development
Kulkarni, P. M., Alemayehu, D., Qu, Y., Backenroth, D., Millen, B. A., Fu, H., der Elst, W. V., Roychoudhury, S., Price, K., Chen, T., et al. (2025) · Handbook of statistics · doi:10.1016/bs.host.2025.04.005
Self-citationSanfilippo, G. L., Badami, G. D., Manna, M. P. L., Pizzo, M., Lio, D., Giammanco, A., & Caccamo, N. (2026) · Biomolecules · doi:10.3390/biom16081111
“Vaccines have played a remarkable role in the management and containment of the SARS-CoV-2 pandemic, significantly contributing to reducing the severity of infections [1].”
Tay, E., Dymock, M., Lopez, L. K., et al. (2024) · medRxiv · doi:10.1101/2024.03.03.24303687
“Compared to older people, younger people are assumed to be more likely to have a moderate or severe reaction (henceforth referred to as severe reaction) [18, 20], but less likely to respond to a health survey [21, 22], and less likely to seek medical attention if they experience an AEFI.”
BackgroundInfluentialJo, S., Min, K., & Cho, S. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108997
Eventos adversos asociados a post-vacunas COVID 19 en pacientes de una Unidad de Medicina Familiar
Perez-Contreras, N., CONTRERAS, I. P., Santamaria-Garcia, S., et al. (2023) · Medicina e Investigación Universidad Autónoma del Estado de México · doi:10.36677/medicinainvestigacion.v11i1.20305
Rondanina, G., Webber, T. B., D’Ecclesiis, O., Musso, M., Briata, I. M., Provinciali, N., Boitano, M., Clavarezza, M., D’Amico, M., Defferrari, C., et al. (2024) · Cancers · doi:10.3390/cancers16234012
“This contrasts with the robust 95% efficacy observed in healthy individuals following administration of the BNT162b2 vaccine [23].”
Dulipsingh, L., Lang, M., Diffenderfer, M. R., Cook, L., Puff, J., Diaz, L., He, L., & Schaefer, E. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4131160
Cotter, C. A., Americo, J. L., Earl, P. L., & Moss, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.03.518963
ATUALIZAÇÕES DA CORTICOTERAPIA NOS PACIENTES EM SUPORTE VENTILATÓRIO PELA COVID-19
Xavier, L. C., Assis, D. S., do Nascimento, I. C. M., Barreto, L. M. L., Borges, L. C. A., Silva, L. E. D. O., Faria, L. P., Souza, M. A. G., Brito, M. S. R., Silva, S. D. C., et al. (2021) · doi:10.22533/at.ed.59421020920
Mostafa, H. H., & Pinsky, B. A. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0093
COVID-19, One Health, and pandemic prevention
Salkeld, D., Hopkins, S. R., & Hayman, D. T. S. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198825920.003.0015
Bermúdez-Méndez, E., Lenart, K., Cerveira, R. A., Engstrand, O., Hellgren, F., Cagigi, A., Ols, S., Jasny, E., Reinhardt, A., Petsch, B., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01492-y · Cited by 1
COVID-19 Vaccines: A Literature Review
Filho, A. D. S. V., Bianchetti, B. M., Peixer, C. M., Cordón, M. S., Rocha, M. D. O. F., & Vasconcelos, V. C. R. (2022) · Seven Editora eBooks · doi:10.56238/pacfdnsv1-003
Incidence of adverse events of the Covid-19 vaccine in a population of kidney transplant recipients
Gimeno-Hernán, V., Jiménez, B. P., Flores, I. P., et al. (2024) · Enfermería Nefrológica · doi:10.37551/s2254-28842024013
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.